Product Reports Resources Pricing Login Book a demo

Arcutis

Biotech & Life Sciences · Westlake Village, United States · Founded 2016 · IPO 2020

Focuses on medical dermatology, leveraging innovations in inflammation and immunology MoreLess

Arcutis Biotherapeutics is a biopharmaceutical company specializing in the development of innovative therapies for dermatological diseases. The company focuses on filling the innovation gap in medical dermatology by leveraging recent advancements in inflammation and immunology. Arcutis serves patients suffering from skin conditions such as psoriasis, eczema, and seborrheic dermatitis. Operating in the biopharmaceutical market, the company employs a business model centered around research and development, clinical trials, and commercialization of its proprietary drug formulations. Revenue is generated through the sale of these specialized therapies once they receive regulatory approval. The leadership team, which includes top dermatologists and a leading topical drug formulator, brings unparalleled expertise to the company's mission of becoming a leader in dermatological innovation.

Keywords: biopharmaceutical, dermatology, psoriasis, eczema, seborrheic dermatitis, inflammation, immunology, drug development, clinical trials, proprietary formulations.

Valuation $3.25B
Revenue $500M
EBITDA $67M
Total funding $100–500M

Talent graph

Arcutis's talent

Book a demo to see the people
Team profiled 16 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 9 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

5 investors on Arcutis's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage
Frazier Healthcare Partners
OrbiMed
Series B+ 3 investors entered at this stage
HBM Healthcare Investments
Vivo Capital
SLR Capital Partners

Global footprint

Where Arcutis has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States93.7%
🇨🇦 Canada6.3%
2 countries shown
Web traffic by country
20K monthly visits
across markets
🇺🇸 United States62%
🇨🇦 Canada29.5%
🇮🇳 India8.5%
Top 3 markets shown

Patent intelligence

$40M patent portfolio · 32 active families

Estimated portfolio value
$40M
1.2% of market cap · comparable to top peer Camurus ($49M)
32 active patent families
Where Arcutis innovates Active agentCetostearyl alcoholEfficacyMedicinal chemistryPathology

Where Arcutis concentrates vs peers

Each axis is a top-10 topic across Arcutis and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Arcutis

An AI-synthesized read of the highest-engagement posts about Arcutis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arcutis on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.